Prime Medicine, Inc.
PRMEPrime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PM359 | Phase 2 | Chronic Granulomatous Disease | - | - |
Frequently asked questions
What is in Prime Medicine, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Prime Medicine, Inc.'s (PRME) pipeline across Phase 2. Its lead program is PM359 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Prime Medicine, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Prime Medicine, Inc. (PRME) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRME biotech catalysts?→
Add PRME to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Prime Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.